HIPRA ITALIA organized the launch of YURVAC® RHD, the first recombinant RHD vaccine indicated for protection against rabbit haemorrhagic disease caused by both the classic and variant strains, including highly virulent strains.
The event took place over two days and two different locations: Hotel il Giardino dei Tigli in the Piomonte region on March 5, and Hotel Lemi in the Campania region on March 6. In total, more than 40 professionals from the rabbit industry attended.
The presentation began with an institutional introduction by Claudio Valli, Sales Manager of HIPRA ITALIA, who shared HIPRA's vision and growth in the rabbit farming sector. Subsequently, Sandra Gascón, Global Product Manager of HIPRA, detailed the positive results obtained in preclinical and clinical studies conducted during the development and registration of the YURVAC® RHD vaccine.
Finally, to conclude the event, there was the interesting participation of F. Xavier Mora, an independent veterinary consultant with over 30 years of experience in the rabbit farming sector, advising farms and rabbit companies and training commercial teams and veterinary students. He shared several clinical cases related to rabbit hemorrhagic disease and highlighted the crucial role of our innovative vaccine YURVAC® RHD in its prevention and outbreak resolution.
The day ended with a lunch, during which participants had the opportunity to exchange experiences and ask more detailed questions about our new vaccine.
With this launch, YURVAC® RHD continues its expansion across Europe, and HIPRA reaffirms its position as a reference in Italy in the control of rabbit hemorrhagic disease, strengthening its commitment to rabbit health.
